8-KOther EventsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Jan 30, 2008)

Filed January 30, 2008For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on January 30, 2008, announcing that the company was scheduled to present at the Wachovia Securities 2008 Healthcare Conference on January 30, 2008. During this presentation, Quest Diagnostics intended to reaffirm its previously issued financial guidance for the full year 2007. Specifically, the company reiterated its expectation for 2007 revenues to be in the range of $6.6 billion to $6.7 billion. Furthermore, Quest Diagnostics confirmed its projected earnings per diluted share from continuing operations to be between $2.84 and $2.91, excluding approximately $0.04 per share related to special charges incurred in the first quarter of 2007. This filing primarily served to inform investors of the company's participation in the conference and its continued confidence in its 2007 financial outlook.

Key Highlights

  • 1Quest Diagnostics to present at Wachovia Securities 2008 Healthcare Conference on January 30, 2008.
  • 2Company will reaffirm its 2007 revenue guidance of $6.6 billion to $6.7 billion.
  • 3Company will reaffirm its 2007 earnings per diluted share (EPS) guidance from continuing operations.
  • 4Reaffirmed 2007 EPS guidance is between $2.84 and $2.91.
  • 5The EPS guidance excludes approximately $0.04 per share in special charges from Q1 2007.
  • 6Press release announcing the conference participation and guidance reaffirmation is attached as Exhibit 99.1.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Quest Diagnostics' participation in the Wachovia Securities 2008 Healthcare Conference and to reaffirm its previously issued financial guidance for the full year 2007, indicating the company's continued confidence in its financial performance.

Quest Diagnostics reaffirmed its guidance for 2007 revenues to be between $6.6 billion and $6.7 billion, and its earnings per diluted share from continuing operations to be between $2.84 and $2.91, after excluding approximately $0.04 per share in special charges from the first quarter of 2007.

No, this filing does not provide new financial results. It serves to reaffirm existing guidance for the full year 2007, indicating no changes to the company's outlook at the time of the filing.

The press release announcing the conference participation and guidance reaffirmation is attached to the 8-K filing as Exhibit 99.1, and is incorporated by reference. Investors can refer to this press release for additional context.